Relation of asymmetric dimethylarginine levels with conventional risk score systems in the healthy subjects with positive family history for coronary artery disease;Koroner arter hastalıǧı için aile öyküsü pozitif olan bireylerde asimetrik dimetilarjinin düzeylerinin geleneksel risk puanlama yöntemleri ile ilişkisi

Anadolu Kardiyoloji Dergisi

Volumn 11, Issue 2, 2011, Pages 114-118

  Satilmişoǧlu, Hulusi ^a   Özhan, Hakan ^a   Albayrak, Sinan ^a   Kaya, Ahmet ^a   Erden, Ismail ^a   Yazici, Mehmet ^a  

^a Yogun Bak m Section   (Turkey)

Author keywords

Asymmetric dimethylarginine; Coronary artery disease; Risk

Indexed keywords

C REACTIVE PROTEIN; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; TRIACYLGLYCEROL; ARGININE; DIMETHYLARGININE; DRUG DERIVATIVE;

ADULT; AGE; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FAMILY HISTORY; GENDER; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MORBIDITY; OBSERVATIONAL STUDY; RELATIVE; SCORING SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; CASE CONTROL STUDY; FEMALE; GENETICS; MALE; METABOLISM; RISK ASSESSMENT; RISK FACTOR;

ADULT; ARGININE; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 79952509424     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: 10.5152/akd.2011.029     Document Type: Article

References (20)

1. Cooper R, Cutler J, Desvigne-Nickens P, Fortmann SP, Friedman L, Havlik R, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation 2000; 102: 3137-47.
2. Onat A, Karabulut A, Esen AM, Uyarel H, Özhan H, Albayrak S, et al. TEKHARF Çali{dotless}şmasi{dotless} 2005 taramasi{dotless}na ilişkin mortalite ve koroner olay analizi. Türk Kardiyol Dern Arş 2006; 34: 149-53.
3. Dusting GJ, Fennessy P, Yin ZL, Gurevich V. Nitric oxide in atherosclerosis: vascular protector or villain?, Clin Exp Pharmacol Physiol Suppl 1998; 25: S34-41.
4. Böger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009; 119: 1592-600.
5. Leong T, Zylberstein D, Graham I, Lissner L, Ward D, Fogarty J, et al. Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the Population Study of women in Gothenburg. Arterioscler Thromb Vasc Biol 2008; 28: 961-7.
6. Maas R, Schulze F, Baumert J, Löwel H, Hamraz K, Schwedhelm E, et al. Asymmetric dimethylarginine, smoking, and risk of coronary heart dis- ease in apparently healthy men: prospective analysis from the popula- tion-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg study and experimental data. Clin Chem 2007; 53: 693-701.
7. Böger RH. Asymmetric dimethylarginine: a novel risk marker in cardiovascular medicine and beyond. Ann Med 2006; 38: 126-36.
8. Tonstad S, Thorsrud H, Torjesen PA, Seljeflot I. Do novel risk factors differ between men and women aged 18 to 39 years with a high risk of coronary heart disease? Metabolism 2007; 56: 260-6.
9. Iribarren C, Husson G, Sydow K, Wang B, Sidney S, Cooke JP. Asymmetric dimethylarginine and coronary artery calcification in young adults entering middle age: the CARDIA Study. Eur J Cardiovasc Prev Rehabil 2007; 14: 222-9.
10. Smith SC Jr, Greenland P, Grundy SM. AHA Conference Proceedings. Prevention conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: executive summary. American Heart Association. Circulation 2000; 101: 111-6.
11. Onat A. A proposed scoring scheme for assessing coronary risk in Turkish adults. Türk Kardiyol Dern Arş 2002; 30: 604-11.
12. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-5.
13. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842-7.
14. Wang D, Strandgaard S, Iversen J, Wilcox CS. Asymmetric dimethylarginine, oxidative stress and vascular nitric oxide synthase in essential hypertension. Am J Physiol Regul Integr Comp Physiol 2009; 296: 195-200.
15. Yada T, Kaji S, Akasaka T, Mochizuki S, Ogasawara Y, Tanemoto K, et al. Changes of asymmetric dimethylarginine, nitric oxide, tetrahydrobiopterin, and oxidative stress in patients with acute myocardial infarction by medical treatments. Clin Hemorheol Microcirc 2007; 37: 269-76.
16. Hori T, Matsubara T, Ishibashi T, Ozaki K, Tsuchida K, Mezaki T, et al. Significance of asymmetric dimethylarginine (ADMA) concentrations during coronary circulation in patients with vasospastic angina. Circ J 2003; 67: 305-11.
17. Böger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the 'L- arginine paradox' and acts as a novel cardiovascular risk factor. J Nutr 2004; 134: 2842-7.
18. Smith SC Jr, Milani RV, Arnett DK, Crouse JR 3rd, McDermott MM, Ridker PM, et al. Atherosclerotic Vascular Disease conference: Writing Group II: risk factors. Circulation 2004; 109: 2613-6.
19. Frantzen F, Faaren AL, Alfheim I, Nordhei AK. Enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem 1998; 44; 311-6.
20. Kaul S, Zadeh AA, Shah PK. Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated. J Am Coll Cardiol 2006: 48; 914-23.